Myriad(US:MYGN) Globenewswire·2026-02-23 21:05Core Insights - Myriad Genetics reported financial results for Q4 2025, showing stable revenue but a slight decline in full-year revenue for 2025, with expectations for growth in 2026 driven by new test launches [2][5][15] Financial Performance - Q4 2025 revenue was $209.8 million, consistent with Q4 2024, but grew 4% year-over-year when excluding an $8.1 million headwind [5][21] - Full-year 2025 revenue was $824.5 million, a decrease of 2% year-over-year, but grew 2% when excluding headwinds [5][21] - Q4 2025 gross margin was 70.0%, in line with Q3 2025 [5] - The company reported a GAAP net loss of $7.9 million, or $0.08 per share, while adjusted EPS was $0.04 per share [5][24] Operational Highlights - Total test volumes in Q4 2025 were 382,000, a 2% increase year-over-year [6] - Hereditary cancer testing volume grew by 9% year-over-year, while Prolaris prostate cancer test volume increased by 12% [5][11] - The Women's Health business generated $88.5 million in revenue in Q4 2025, while the Oncology business generated $84.7 million [9][12] Future Outlook - The company plans to launch three significant new tests in 2026, including Precise MRD for breast cancer, AI-enabled Prolaris, and FirstGene prenatal screen [3][15] - Full-year 2026 revenue guidance is set between $860 million and $880 million, with Q1 2026 revenue expected to be between $200 million and $203 million [15][14] Cash Flow and Liquidity - Q4 2025 cash flow from operations was $10.6 million, with adjusted operating cash flow of $17.9 million [8] - As of the end of Q4 2025, the company had cash and cash equivalents of $149.6 million [8][26]